Funding
Series B · Biotech

Kytopen secures Series B financing from Telegraph Hill Partners

Telegraph Hill Partners backed cellular-engineering technology on undisclosed terms.

Updated Oct 16, 2026By RoundOS Funding desk

Kytopen secured Series B financing on April 7, with participation from Telegraph Hill Partners. The amount was not disclosed. The company develops non-viral, continuous-flow cellular engineering for cell-therapy manufacturing.

Funding history

Series B · This roundUndisclosed

Sources

  1. Kytopen Corpprojectstartups.com
  2. prnewswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Fairy Devices

Tokyo company developing wearable devices and remote-assistance software for industrial field workers.

UndisclosedJICN equity investment · Oct 23, 2026

Related